Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Stacy E. Croteau, MD, MMS

  • Medical Director, Boston Hemophilia Center
  • Physician
  • Assistant Professor of Pediatrics, Harvard Medical School

Appointment Phone

  • 617-632-3270
  • 888-733-4662

Fax

  • 617-730-0641

General

Treatment Centers

Discipline

Clinical Interests

Hemophilia, Rare bleeding disorders, Thrombosis

Location

Background

Board Certifications

  • Pediatric Hematology-Oncology, 2015
  • Pediatrics, 2010

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 2014

Residency

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics, 2010

Medical School

  • Brown Medical School, 2007

Biography

Dr. Croteau is a pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, where she specializes in bleeding and clotting disorders. She completed her undergraduate and medical education at Brown University and then pursued training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Croteau joined the Boston Hemophilia Center as the associate director in 2014 and became the medical director in 2019. She enjoys clinical care of pediatric patients and leading research efforts to push the frontier of the quality and innovation in our current standards of medical practice. She currently serves at the primary investigator for several industry-sponsored and investigator initiated clinical trials and as the national chair of the American Thrombosis Hemostasis Network (ATHN)/National Hemophilia Program Coordinating Center (NHPCC) Transition Working Group. She also serves on the American Society of Hematology's Scientific Committee for Hemostasis. Her primary areas of academic interest are early drug development, advancing an approach for rationally designed personalized-prophylaxis regimens in hemophilia, and quality improvement efforts targeting patient transition from pediatric to adult care.